Literature DB >> 21717133

Cancer-initiating enriched cell lines from human glioblastoma: preparing for drug discovery assays.

Miriam Romaguera-Ros1, María Peris-Celda, Jorge Oliver-De La Cruz, Josefa Carrión-Navarro, Arantxa Pérez-García, Jose Manuel García-Verdugo, Angel Ayuso-Sacido.   

Abstract

Glioblastoma multiforme (GBM) is the most lethal type of brain tumour in the adult humans. The cancer-initiating cell (CIC) hypothesis supports the notion that failures in current approaches to GBM treatment might be attributed to the survival of the CIC subpopulation. Recent evidence shows the idea that using CIC-enriched cell lines derived from human GBM as new targets for drug discovery programs, may improve the chance of successfully translating the basic research findings into clinical trials. Although this approach appears promising, many important biological and technical issues (characterization of functional CIC markers, inter- and intra-tumoral CIC heterogeneity, and isolation and maintenance inconsistency) need to be resolved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21717133     DOI: 10.1007/s12015-011-9283-1

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  96 in total

1.  Targeting cancer stem cells through L1CAM suppresses glioma growth.

Authors:  Shideng Bao; Qiulian Wu; Zhizhong Li; Sith Sathornsumetee; Hui Wang; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 2.  Recurrent glioblastoma multiforme: a review of natural history and management options.

Authors:  Lewis C Hou; Anand Veeravagu; Andrew R Hsu; Victor C K Tse
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

Review 3.  Tumoral invasion in the central nervous system.

Authors:  Y A De Clerck; H Shimada; I Gonzalez-Gomez; C Raffel
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 4.  Designer therapies for glioblastoma multiforme.

Authors:  Sith Sathornsumetee; Jeremy N Rich
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

5.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

6.  Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells.

Authors:  Y M Yang; J W Chang
Journal:  Cancer Invest       Date:  2008-08       Impact factor: 2.176

7.  CD44 mediates human glioma cell adhesion and invasion in vitro.

Authors:  A Merzak; S Koocheckpour; G J Pilkington
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

8.  Phenotypic characterization of human colorectal cancer stem cells.

Authors:  Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

9.  Glioblastomas with oligodendroglial component - common origin of the different histological parts and genetic subclassification.

Authors:  Barbara Klink; Ben Schlingelhof; Martin Klink; Karen Stout-Weider; Stephan Patt; Evelin Schrock
Journal:  Anal Cell Pathol (Amst)       Date:  2010       Impact factor: 2.916

10.  Cryopreservation of neurospheres derived from human glioblastoma multiforme.

Authors:  Yuk-Kien Chong; Tan-Boon Toh; Norazean Zaiden; Anuradha Poonepalli; Siew Hong Leong; Catherine Ee Ling Ong; Yiting Yu; Patrick B Tan; Siew-Ju See; Wai-Hoe Ng; Ivan Ng; Manoor P Hande; Oi Lian Kon; Beng-Ti Ang; Carol Tang
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

View more
  6 in total

Review 1.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

Review 2.  Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma.

Authors:  Shin-Yi Liu; Ming-Fu Chiang; Yu-Jen Chen
Journal:  Exp Biol Med (Maywood)       Date:  2014-11-27

3.  Isolation of cancer stem cells from three human glioblastoma cell lines: characterization of two selected clones.

Authors:  Fortunata Iacopino; Cristiana Angelucci; Roberto Piacentini; Filippo Biamonte; Annunziato Mangiola; Giulio Maira; Claudio Grassi; Gigliola Sica
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

Review 4.  Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.

Authors:  Yiping Wen; Jing Cai; Yaya Hou; Zaiju Huang; Zehua Wang
Journal:  Oncotarget       Date:  2017-06-06

5.  Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies.

Authors:  Doreen William; Christina Susanne Mullins; Björn Schneider; Andrea Orthmann; Nora Lamp; Mathias Krohn; Annika Hoffmann; Carl-Friedrich Classen; Michael Linnebacher
Journal:  J Transl Med       Date:  2017-02-09       Impact factor: 5.531

6.  Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Authors:  Richard E Kast; Nicolas Skuli; Georg Karpel-Massler; Guido Frosina; Timothy Ryken; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2017-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.